Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study

Figure 1

Kaplan–Meier curves of the overall and progression-free survival from the initiation of olaparib (n = 69).

(a)

(b)